Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumor
Conditions
Keywords
Solid Tumors, NSCLC
Brief summary
This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in Chinese subjects with advanced solid tumors and in Chinese subjects with advanced or metastatic EGFR-mutant NSCLC.
Detailed description
The Part A of this phase I trial is an abbreviated dose escalation study of BBP-398 following the USA mono dose escalation study (Study NAV- 1001, clinicaltrials.gov ID NCT04528836). The purpose of this part is to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity in Chinese subjects with advanced solid tumors. The Part B of this study is to explore the safety, tolerability and efficacy of BBP-398 in Chinese subjects with advanced or metastatic EGFR- mutant NSCLC at MTD and/or RP2D. This Phase I study will provide supportive data to enable Chinese patients to join the combo dose escalation and expansion studies and/or other clinical trials of BBP-398.
Interventions
DRUGBBP-398
BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
Sponsors
LianBio LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1\. Patients must have the ability to understand and the willingness to sign a written informed consent document 2 Patients must be willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures 3. Age ≥18, male or female 4.Dose escalation: locally advanced or metastatic solid tumors Dose expansion: Advanced or metastatic EGFR-mutant NSCLC 5. Patients must have measurable disease by RECIST v1.1. 6. Patients must have an ECOG performance status (PS) ≤2 7.Patients with a life expectancy of ≥12 weeks. 8. Patients must have adequate organ function
Exclusion criteria
1. Patients with a known additional malignancy that is progressing or requires active treatment 2. Patients who have previously received a SHP-2 inhibitor 3. Patients who are hypersensitivity to SHP-2 inhibitor or any ingredients 4. Treatment with any of the related anti-cancer therapies prior to the first dose of BBP-398 within the stated timeframes 5. Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection. 6. Patients with any of the cardiac-related issues or findings 7. Patients with a history of CVA, myocardial infarction or unstable angina within the previous 6 months before starting therapy. 8. Patients with known central nervous system (CNS) tumors 9. Patients with known active CNS metastases and/or carcinomatous meningitis. 10. Patients with persisting toxicity related to prior therapy. 11. Patients who have undergone major surgery within 4 weeks prior to study enrollment. 12. Pregnant or breastfeeding female patients. 13. Patients with inability to swallow oral medications or with gastrointestinal illness that would preclude the absorption of an oral agent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of Maximum Tolerated Dose (MTD) of BBP-398 | Completion of 1 Cycle (28 days) | The MTD will be based on DLT |
| Determination of anti-tumor activity of BBP-398 | Completion of 1 Cycle (28 days) | Anti-tumor activity will be defined by objective response rate (ORR, complete response + partial response rate) and duration of response (DOR) according to RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Terminal half-life (t1/2) of BBP-398 | Approximately 6months | Terminal half-life (t1/2) after single and multiple dose administration of BBP-398 |
| Part A: Area under the plasma concentration-time curve (AUC) of BBP-398 | Approximately 6 months | Area under the plasma concentration versus time curve after single and multiple dose administration of BBP-398 |
| Part A:Maximum plasma concentration (Cmax) of BBP-398 | Approximately 6 months | Maximum plasma concentration of BBP-398 after single and multiple dose administration of BBP-398 |
| Part B: Concentration of BBP-398 in plasma | Approximately 6 months | To evaluate BBP-398 plasma concentration after multiple dose administration of BBP-398. |
| Part A: Concentration of BBP-398 in urine | Approximately 6 months | To evaluate BBP-398 excretion via urine after single and multiple dose administration of BBP-398. |
| Part A:Time to reach Cmax (Tmax) of BBP-398 | Approximately 6 months | The amount of time to reach Cmax after single and multiple dose administration of BBP-398 |
Countries
China
Outcome results
None listed